JP2003517011A5 - - Google Patents

Download PDF

Info

Publication number
JP2003517011A5
JP2003517011A5 JP2001544880A JP2001544880A JP2003517011A5 JP 2003517011 A5 JP2003517011 A5 JP 2003517011A5 JP 2001544880 A JP2001544880 A JP 2001544880A JP 2001544880 A JP2001544880 A JP 2001544880A JP 2003517011 A5 JP2003517011 A5 JP 2003517011A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001544880A
Other languages
Japanese (ja)
Other versions
JP2003517011A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/033866 external-priority patent/WO2001043742A1/en
Publication of JP2003517011A publication Critical patent/JP2003517011A/ja
Publication of JP2003517011A5 publication Critical patent/JP2003517011A5/ja
Pending legal-status Critical Current

Links

JP2001544880A 1999-12-16 2000-12-14 レフルノミドの新規な製法及び新しい結晶形態 Pending JP2003517011A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US17122899P 1999-12-16 1999-12-16
US17123799P 1999-12-16 1999-12-16
US60/171,237 1999-12-16
US60/171,228 1999-12-16
US18264700P 2000-02-15 2000-02-15
US60/182,647 2000-02-15
US20241600P 2000-05-08 2000-05-08
US60/202,416 2000-05-08
PCT/US2000/033866 WO2001043742A1 (en) 1999-12-16 2000-12-14 Novel processes for making- and a new crystalline form of- leflunomide

Publications (2)

Publication Number Publication Date
JP2003517011A JP2003517011A (ja) 2003-05-20
JP2003517011A5 true JP2003517011A5 (enExample) 2005-12-22

Family

ID=27496942

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001544880A Pending JP2003517011A (ja) 1999-12-16 2000-12-14 レフルノミドの新規な製法及び新しい結晶形態

Country Status (15)

Country Link
US (3) US6610718B2 (enExample)
EP (1) EP1242077A4 (enExample)
JP (1) JP2003517011A (enExample)
KR (1) KR20020067545A (enExample)
CN (1) CN1411373A (enExample)
AU (1) AU779931B2 (enExample)
CA (1) CA2397601A1 (enExample)
CZ (1) CZ20022000A3 (enExample)
HR (2) HRP20050176A2 (enExample)
HU (1) HUP0204069A3 (enExample)
IL (1) IL149792A0 (enExample)
PL (1) PL356243A1 (enExample)
SK (1) SK8332002A3 (enExample)
WO (1) WO2001043742A1 (enExample)
YU (1) YU45102A (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE207065T1 (de) * 1997-08-08 2001-11-15 Aventis Pharma Gmbh Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
HRP20050176A2 (en) * 1999-12-16 2005-08-31 Teva Pharmaceutical Industries Ltd. Novel processes for making - and a new crystalline form of-leflunomide
AU2001228454A1 (en) * 2000-01-13 2001-07-24 Merck Patent G.M.B.H Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary
KR20020072312A (ko) * 2000-02-15 2002-09-14 테바 파마슈티컬 인더스트리즈 리미티드 레플루노미드를 합성하는 방법
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
WO2006103506A1 (en) * 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Sertraline-containing pharmaceutical compositions and a process for preparation thereof
WO2008040149A1 (en) * 2006-09-05 2008-04-10 Dexian Dou Composition and method for treating immune-mediated skin disorders
CN101143834B (zh) * 2006-09-15 2010-09-08 欣凯医药化工中间体(上海)有限公司 N-(4-三氟甲基苯)-2-氰基-3-羟基丁烯酰胺钠盐的多晶型及其制备方法
AU2008272685B2 (en) 2007-06-29 2013-04-18 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
NZ585438A (en) 2007-10-24 2012-09-28 Generics Uk Ltd Novel crystalline forms of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yI]-benzenesulfonamide
NZ587793A (en) 2008-02-08 2012-06-29 Generics Uk Ltd Process for preparing bosentan
CA2741928A1 (en) 2008-11-03 2010-06-03 Generics [Uk] Limited Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
CN101817797B (zh) * 2009-02-26 2013-04-10 江苏亚邦爱普森药业有限公司 高纯度3-甲基-n-[4-(三氟甲基)苯基]-4-异噁唑甲酰胺的合成方法
KR102495018B1 (ko) 2013-11-15 2023-02-06 아케비아 테라퓨틱스 인코포레이티드 {[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노}아세트산의 고체형, 이의 조성물 및 용도
US11801232B2 (en) * 2019-11-27 2023-10-31 Yale University Targeting of ARID1A-deficient cancers by inhibiting de novo pyrimidine synthesis pathway
CN112898215B (zh) * 2021-02-04 2022-11-08 美罗药业股份有限公司 一种来氟米特晶型i的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US5268382A (en) * 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
GB8619432D0 (en) * 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds
WO1991017748A1 (de) * 1990-05-18 1991-11-28 Hoechst Aktiengesellschaft Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
DE19610955A1 (de) * 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
DE19711800A1 (de) * 1997-03-21 1998-09-24 Hoechst Ag Verlängerung der Expression von transgenen Proteinen durch immunmodulierende Behandlung
ATE207065T1 (de) * 1997-08-08 2001-11-15 Aventis Pharma Gmbh Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
EP0933633A1 (en) * 1997-12-11 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Process for obtaining L-dihydroorotic acid and use thereof
US7691890B2 (en) * 1998-03-11 2010-04-06 James W. Williams Anti-viral uses of leflunomide products
US6303652B1 (en) * 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DK1196414T3 (da) * 1999-06-25 2003-11-24 Vertex Pharma Prolægemiddel af carbamathæmmer for IMPDH
HRP20050176A2 (en) * 1999-12-16 2005-08-31 Teva Pharmaceutical Industries Ltd. Novel processes for making - and a new crystalline form of-leflunomide
KR20020072312A (ko) * 2000-02-15 2002-09-14 테바 파마슈티컬 인더스트리즈 리미티드 레플루노미드를 합성하는 방법
US6548527B2 (en) * 2000-03-27 2003-04-15 The General Hospital Corporation Treatments for immune-mediated ear disorders
AU2001284891A1 (en) * 2000-08-14 2002-02-25 Teva Pharmaceutical Industries Ltd. Micronized leflunomide
CA2420279C (en) * 2000-08-24 2011-07-19 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
JP4212278B2 (ja) * 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
US20040229849A1 (en) * 2002-09-24 2004-11-18 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
EP1684820A2 (en) * 2003-08-13 2006-08-02 Medtronic, Inc. Active agent delivery systems including a miscible polymer blend, medical devices, and methods
JP2008511339A (ja) * 2003-08-13 2008-04-17 メドトロニック・インコーポレーテッド 相溶性ポリマーブレンドの単層を含む活性薬剤送達システム、医療用デバイス、及び方法
WO2005023201A2 (en) * 2003-09-09 2005-03-17 Medarex, Inc. Methods for treating rheumatoid arthritis

Similar Documents

Publication Publication Date Title
BE2014C035I2 (enExample)
BE2014C009I2 (enExample)
BE2012C016I2 (enExample)
JP2001053789A5 (enExample)
BE2009C057I2 (enExample)
BE2010C019I2 (enExample)
BE2010C018I2 (enExample)
BRPI0113085B8 (enExample)
JP2003504718A5 (enExample)
BRPI0112928B8 (enExample)
JP2002189570A5 (enExample)
BE2011C041I2 (enExample)
JP2003517011A5 (enExample)
JP2001340059A5 (enExample)
JP2003502841A5 (enExample)
JP2002174840A5 (enExample)
JP2003508532A5 (enExample)
JP2002036392A5 (enExample)
JP2001060626A5 (enExample)
JP2002111941A5 (enExample)
JP2002002451A5 (enExample)
JP2000353208A5 (enExample)
BY5768C1 (enExample)
ECSMU000158U (enExample)
JP2001257843A5 (enExample)